Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

January 2023 in “ Indian Dermatology Online Journal ”

Kabir Sardana, Savitha Bathula, Ananta Khurana

Janus Kinase inhibitors JAK inhibitors baricitinib tofacitinib ritlecitinib ifidancitinib Alopecia Areata JAK3 inhibitors autoimmune hair loss JAK pathway JAKibs JAK3ibs AA

TLDR No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

The document discusses the role of Janus Kinase inhibitors (JAKibs) in treating Alopecia Areata (AA), a chronic autoimmune hair loss condition. Various JAKibs like baricitinib, tofacitinib, ritlecitinib, and ifidancitinib have shown efficacy in treating AA, but the ideal one is yet to be determined due to factors like side effects and recurrence after discontinuation. The document suggests that JAK3 inhibitors (JAK3ibs) show high efficacy with fewer side effects, making them a promising future treatment for AA. However, further studies are needed to assess their long-term results, side effect profiles, and comparisons with existing systemic drugs for AA. The document concludes that JAK3ibs could potentially replace current JAKib drugs for AA treatment.

View this study on journals.lww.com →

Discuss this study in the Community →

Cited in this study

26 / 26 results

research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata

13 citations , September 2022 in “Frontiers in immunology”

Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.

research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

8 citations , June 2022 in “Frontiers in Medicine”

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , May 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Systematic Review: Alopecia Areata and Tofacitinib in Pediatric Patients

2 citations , April 2022 in “Cutaneous and Ocular Toxicology”

Tofacitinib may help treat hair loss in children with alopecia areata.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations , April 2022 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata

40 citations , June 2021 in “Clinical, cosmetic and investigational dermatology”

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata

42 citations , April 2021 in “JCI insight”

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses

11 citations , February 2021 in “Journal of Cosmetic Dermatology”

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

research Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity

57 citations , July 2019 in “British journal of dermatology/British journal of dermatology, Supplement”

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , April 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

research High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata

46 citations , October 2018 in “JCI insight”

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

research JAK Inhibitors for Treatment of Alopecia Areata

63 citations , September 2018 in “The journal of investigative dermatology/Journal of investigative dermatology”

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , July 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

$Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study$

research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study

11 citations , January 2018 in “Acta dermato-venereologica”

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents

28 citations , January 2018 in “Journal of Investigative Dermatology Symposium Proceedings”

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

$Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series$

research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series

44 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction

27 citations , September 2017 in “Archives of Dermatological Research”

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.

research Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series

16 citations , July 2017 in “Rheumatology and Therapy”

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth

159 citations , October 2015 in “Science Advances”

Blocking JAK-STAT signaling can lead to hair growth.

research The Role of Lymphocytes in the Development and Treatment of Alopecia Areata

60 citations , September 2015 in “Expert Review of Clinical Immunology”

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , December 2014 in “Journal of Investigative Dermatology”

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Familial Aggregation of Alopecia Areata

295 citations , April 2006 in “Journal of the American Academy of Dermatology”

Alopecia areata, a common autoimmune hair loss condition, often runs in families.

8 / 8 results

research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata

August 2023 in “International journal of research in dermatology”

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

January 2023 in “Indian Dermatology Online Journal”

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib

1 citations , February 2022 in “JAAD case reports”

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations , February 2018 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata

30 citations , June 2017 in “Journal of cutaneous medicine and surgery”

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

39 citations , April 2016 in “Case Reports in Dermatology”

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.